Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes

View/ Open
Access
info:eu-repo/semantics/embargoedAccessDate
2019Author
Esin, EceÇakmak Öksüzoǧlu, Berna
Bilici, Ahmet Erkan
Çiçin, İrfan
Köstek, Osman
Kaplan, Mehmet Ali
Aksoy, Sercan
Aktaş, Burak Yasin
Özdemir, Özlem
Alacacıoğlu, Ahmet
Çabuk, Devrim
Sümbül, Ahmet Taner
Sakin, Abdullah
Paydaş, Semra
Yetişir, Ersin
Er, Özlem
Korkmaz, Taner
Yıldırım, Nilgün
Şakalar, Teoman
Demir, Hacer
Artaç¸, Mehmet
Karaaǧaç, Mustafa
Harputluoǧlu, Hakan
Bilen, Ebru
Erdur, Erkan
Deǧirmencioǧlu, Serkan
Aliyev, Altay
Çil, Timuçin
Olgun, Polat
Başaran, Gül Atalay
Gümüşay, Özge
Demir, Atakan
Tanrıkulu, Eda
Yumuk, Perran Fulden
İmamoğlu, İnanç
Oyan, Başak
Çetin, Bülent Eren
Haksöyler, Veysel
Karadurmuş, Nuri
Ertürk, İsmail
Evrensel, Türkkan
Yılmaz, Hasan
Beypınar, İsmail
Koçer, Murat
Pilancı, Kezban Nur
Şeker, Mesut Metin
Ürün, Yüksel
Yıldırım, Nuriye O.
Eren, Tülay
Demirci, Umut
Metadata
Show full item recordCitation
Esin, E., Çakmak Öksüzoğlu, B., Bilici, A. E., Çiçin, İ., Köstek, O., Kaplan M. A. … Demirci, U. (2019). Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes. Cancer Chemotherapy and Pharmacology, 83(1), 131-143. https://dx.doi.org/10.1007/s00280-018-3712-7Abstract
PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.
WoS Q Kategorisi
Q3xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q1Source
Cancer Chemotherapy and PharmacologyVolume
83Issue
1Collections
- Makale Koleksiyonu [3522]
- PubMed İndeksli Yayınlar Koleksiyonu [3863]
- Scopus İndeksli Yayınlar Koleksiyonu [5975]
- WoS İndeksli Yayınlar Koleksiyonu [6094]